Although the identification of PD biomarkers in patients is still a goal to achieve (Jimenez-Jimenez et al., 2014; Costa et al., 2015), increased expression or aggregation of α-synuclein in animal models can be important evidence of validity (Cannon et al., 2009; Fornai et al., 2005; Yuan et al., 2015), including in the reserpine progressive protocol (Beserra-Filho et al., 2022; Leao et al., 2017; Leao et al., 2021; de Gois et al., 2025). This evidence concerns the gene SNCA and Parkinson disease.